{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:32:04Z","timestamp":1784129524245,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Hepatitis B (HBV) remains a major public health concern in the WHO European Region, causing approximately 32,000 deaths annually as of 2022. Fortunately, HBV vaccination is highly effective in preventing infection. The WHO Regional Office for Europe established criteria for countries to be validated in reaching interim targets for HBV control through immunization, advancing toward the goal of hepatitis elimination. Belarus, Georgia, Kyrgyzstan, Moldova, Turkmenistan, and Uzbekistan conducted national HBV serosurveys, which revealed a significant reduction in chronic HBV prevalence among individuals born after the introduction of universal HBV vaccination in their national immunization programs. We analyzed these serosurvey data and developed a mathematical model to estimate the impact of various vaccination scenarios on HBV-related deaths and severe liver disease. The vaccination scenarios included the current vaccination strategies, as well as two other full-vaccination scenarios\u2014one beginning at vaccine introduction and another starting in 2021 and also a no vaccination scenario. The vaccination scenarios reflect the programmatic context in the countries such as administration of hepatitis B immunoglobulin to infants born to HBsAg positive mothers and hepatitis B sero-prevalence among vaccinated cohorts of children. In the optimal scenarios, we assumed 95% coverage for all these interventions. We used two types of analysis: a birth cohort analysis tracking each cohort until death and a calendar-based analysis assessing the HBV burden annually from the year of vaccine introduction in each country up to 2040. Additionally, we estimated cost savings by calculating the avoided treatment costs and the costs associated with time spent in different health states, based on the outcomes of the calendar-based analysis. Our findings suggest that the existing vaccination programs have reduced HBV-related mortality in birth cohorts by 96.9 to 98.85%. The calendar-based analysis showed that vaccination programs have averted 24.08% (95% CI: 21.73\u201326.43%) of HBV-related deaths since their introduction, with the confidence interval reflecting variation in outcomes across the countries. Furthermore, high vaccination coverage resulted in a saving between US$ 6.07 million and US$ 34.8 million in treatment costs in the countries. This study underscores the importance of timely vaccination strategies as a powerful preventive measure in combating HBV globally.<\/jats:p>","DOI":"10.3389\/fpubh.2025.1567033","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:22:23Z","timestamp":1759728143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Health and economic impact of hepatitis B vaccination in the national immunization program in Belarus, Georgia, Kyrgyzstan, Republic of Moldova, Turkmenistan and Uzbekistan\u2014a modelling study"],"prefix":"10.3389","volume":"13","author":[{"given":"Maryam","family":"Sadeghimehr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liudmila","family":"Mosina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yoon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha Sankar","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"ref1","year":"2024"},{"key":"ref2","year":"2023"},{"key":"ref3","year":""},{"key":"ref4","year":"2023"},{"key":"ref5","author":"Edmunds","year":"2016"},{"key":"ref6","year":"2016"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1080\/21645515.2016.1141845","article-title":"Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013","volume":"12","author":"Chen","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2200837","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200837","article-title":"Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021","volume":"28","author":"Khetsuriani","year":"2023","journal-title":"Euro Surveill"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.puhe.2020.06.024","article-title":"The burden and epidemiology of hepatitis B and hepatitis D in Georgia: findings from the national seroprevalence survey","volume":"185","author":"Kasradze","year":"2020","journal-title":"Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/ije\/dyi206","article-title":"A mathematical model to estimate global hepatitis B disease burden and vaccination impact","volume":"34","author":"Goldstein","year":"2005","journal-title":"Int J Epidemiol"},{"key":"ref12","volume-title":"Fourth meeting of the European Technical Advisory Group of Experts Working Group on Hepatitis B","year":"2022"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.vaccine.2013.01.020","article-title":"Economic evaluation of universal newborn hepatitis B vaccination in China","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/hep.32265","article-title":"The impact of hepatitis B vaccination in the United States, 1999-2018","volume":"75","author":"He","year":"2022","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/infdis\/jiab401","article-title":"Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 Years: Moving Toward the Eradication of HBV","volume":"225","author":"Chang","year":"2022","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modeling study","volume":"3","author":"Polaris","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1473-3099(16)30204-3.Epub","article-title":"Requirements for global elimination of hepatitis B: a modeling study","volume":"16","author":"Nayagam","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1016\/S2214-109X(16)30101-2","article-title":"Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modeling analysis","volume":"4","author":"Nayagam","year":"2016","journal-title":"Lancet Glob Health"},{"key":"ref19","year":"2025"},{"key":"ref20","volume-title":"Fifth meeting of the European Technical Advisory Group of Experts Working Group on Hepatitis B","year":"2023"},{"key":"ref21","volume-title":"National hepatitis elimination profiles","year":"2023"},{"key":"ref22","article-title":"World population prospects 2020","year":"2020"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/cid\/ciab405","article-title":"Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States","volume":"74","author":"Toy","year":"2022","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/cid\/cir270","article-title":"Hepatitis B and the need of booster dose","volume":"53","author":"Leuridan","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2893.2003.00400.x","article-title":"Hepatitis B vaccine\u2013do we need boosters?","volume":"10","author":"Banatvala","year":"2003","journal-title":"J Viral Hepat"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiw142","article-title":"A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen","volume":"214","author":"Simons","year":"2016","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3892\/etm.2017.5474","article-title":"Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells","volume":"15","author":"Gong","year":"2018","journal-title":"Exp Ther Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.idc.2018.02.002","article-title":"Long-term liver disease, treatment, and mortality outcomes among 17,000 persons diagnosed with chronic hepatitis C virus infection: current chronic hepatitis cohort study status and review of findings","volume":"32","author":"Moorman","year":"2018","journal-title":"Infect Dis Clin N Am"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.3748\/wjg.v20.i15.4290","article-title":"Does antiviral therapy reduce complications of cirrhosis?","volume":"20","author":"Chung","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3748\/wjg.v20.i24.7853","article-title":"Antiviral therapy of liver cirrhosis related to hepatitis B virus infection","volume":"2","author":"Lu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cgh.2020.10.023","article-title":"Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.cgh.2019.01.044","article-title":"Long-term outcomes of antiviral therapy for chronic Hepatitis B","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"ref33","first-page":"235","article-title":"Chronic Hepatitis B: A Review of Current Knowledge and Management","volume":"60","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.29800","article-title":"Hepatitis b guidance: AASLD practice guidance","volume":"68","year":"2018","journal-title":"Hepatology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.3748\/wjg.v20.i21.6457","article-title":"Virus-related liver cirrhosis: molecular basis and therapeutic options","volume":"20","author":"Lin","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref36","year":"2016"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e1001774","DOI":"10.1371\/journal.pmed.1001774","article-title":"Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial","volume":"11","author":"Qu","year":"2014","journal-title":"PLoS Med"},{"key":"ref38","article-title":"NIH strategic plan: Details pathway to achieving hepatitis B cure; The strategic plan for Trans-NIH research to cure hepatitis B [Internet]","year":"2021"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1467-842x.2001.tb00566.x","article-title":"An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness","volume":"25","author":"Harris","year":"2001","journal-title":"Aust N Z J Public Health"},{"key":"ref40","year":"2017"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ajog.2022.02.042","article-title":"Comparative efficacy and safety of pharmacologic interventions to prevent mother-to-child transmission of hepatitis B virus: a systematic review and network meta-analysis","volume":"227","author":"Nguyen","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.15171\/middle.east.j.di.v3i2.392","article-title":"Hepatitis B virus infection during pregnancy: transmission and prevention","volume":"3","author":"Navabakhsh","year":"2011","journal-title":"Middle East J Dig Dis"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"100076","DOI":"10.1016\/j.jve.2022.100076","article-title":"Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers","volume":"8","author":"Zhang","year":"2022","journal-title":"J Virus Erad"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11901-011-0109-z","article-title":"Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety","volume":"10","author":"Lam","year":"2011","journal-title":"Curr Hepatol Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2893.2012.01602.x","article-title":"First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice","volume":"19","author":"Pol","year":"2012","journal-title":"J Viral Hepat"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1665-2681(19)30861-0","article-title":"Efficacy and safety of long term entecavir in chronic hepatitis B treatment naive patients in clinical practice","volume":"13","author":"Ridruejo","year":"2014","journal-title":"Ann Hepatol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1567033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:22:24Z","timestamp":1759728144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1567033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":46,"alternative-id":["10.3389\/fpubh.2025.1567033"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1567033","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"article-number":"1567033"}}